If this message does not appear correctly, click this link

Speeches & Conferences

July 21-22   ACT Genomics Introduces Precision Medicine in Lung Cancer Workshop

More and more young people are diagnosed with lung cancer. How do we treat lung cancer more effectively through genomic profiling service? A lung cancer workshop is held by Taiwan Society of Pulmonary and Critical Care Medicine in Taichung to explore the latest trend in lung cancer treatment. ACT Genomics will share more about precision medicine in our display area and provide information on cancer genomic profiling services to physicians.

July 06 & 07  ACT Genomics Research Results Accepted by Best of ASCO SG

ACT Genomics is proud to have two abstracts accepted for moderated poster at Best of ASCO Singapore. The abstracts highlight our experiences in identifying actionable alterations across different solid tumors using comprehensive genomic profiling, as well as experiences in utilizing hot-spot panel to guide lung cancer therapy.

June 20   Professor Harvey Lodish Seminar – Leadership in Innovation and Entrepreneurship

ACT Genomics was invited to participate in a seminar presented by Professor Harvey Lodish on June 20th, 2018 that was organized by the Hong Kong Science and Technology Parks Corporation and Department of Biomedical Sciences, City University of Hong Kong. The seminar entitled: “The Cambridge Biotechnology Ecosystem: Academic Entrepreneurs, New Technologies, and Building Companies to Treat Rare Diseases” shared Prof. Lodish’s experience in establishing his career as an academic entrepreneur and his insights and viewpoints of starting a biotech company. Prof. Lodish, from Massachusetts Institute of Technology Department of Biology and Biological Engineering and Whitehead Institute for Biomedical Research, is a key figure in the development of biotech industry in Massachusetts and a founder of several successful biotech companies. ACT Genomics conversed with Prof. Lodish, Prof. Michael Yang (Head and Yeung Kin Man Chair Professor of Biomedical Sciences, City University of Hong Kong), Prof. Lap-Chee Tsui (President, The Academy of Sciences of Hong Kong and former 14th Vice-Chancellor and President of The University of Hong Kong) and Dr. John Luk (Founder, Arbele, Seattle, WA, USA and HK Science Park, Hong Kong and former Associate Professor, Department of Surgery, The University of Hong Kong).

Image title

June 16  ACT Genomics Symposium Talk at Maayo Wellness Movement Regional Conference in Cebu, Philippines  

ACT Genomics is honoured to be invited as one of the plenary speakers at Maayo Wellness Movement Regional Conference in Cebu, Philippines. In this trip, our Medical Liaison Dr. Liisa Nairismägi discussed how precision medicine is changing the field of cancer management and how CGP has risen to the forefront by dissecting the highly complex composition of cancer.

Image title

June 15   Asian Cancer Alliance for Research and Education – Scientific Meeting on Continuum Care and Precision Oncology in Colorectal Cancer  

ACT Genomics and Sanofi have co-sponsored a scientific meeting on continuum care and precision oncology in colorectal cancer at Conrad Hong Kong Hotel on June 15th, 2018, organized by the Hong Kong Integrated Oncology Centre. The speakers, Prof. Lin Tong Yu, Dr. Angus Leung, Dr. Charles Tsang and Dr. Timothy Yip, gave informative and capturing presentations on the treatment of colorectal cancer over the years.  The meeting has also reinforced the business relationship between Sanofi and ACT Genomics, with a potential project in collaboration.

Image title

June 13   Guangdong General Hospital – To Foster Research in the Greater Bay Area

ACT Genomics was invited to visit Prof. Zhou Hai Yue’s team and laboratory at the Guangdong Academy of Medical Sciences in Guangdong General Hospital.  As a Greater Bay Area initiative, both parties are seeking government funding to embellish current collaborative projects.  This collaboration optimizes the utilization of resources.  The visit has further reinforced the positive cooperative relationship between ACT Genomics and Guangdong General Hospital.

Image title

June 11-13   Shed Light on Tumor Microenvironment in Biomarker & Immuno-oncology World Congress  

The 2018 Biomarker & Immuno-oncology World Congress in Boston brings together biopharma, molecular diagnostics companies and research institutes to discuss the development of biomarkers for immunotherapy. On June 11th, Dr. Kien Thiam Tan presented our newly developed TME (tumor microenvironment) profiling service, aimed to identify patients suitable for immune checkpoint inhibitors.  To find out how our TME profiling service and ACTOnco® comprehensive genomic profiling can accelerate cancer drug development, visit: http://www.actgenomics.com/en/biopharma

Image title

June 12  ACT Genomics at the Government House  

ACT Genomics was invited to attend InvestHK’s Reception for New Foreign and Mainland Companies in Hong Kong at the Government House on June 12th, 2018. ACT Genomics met the Chief Executive, staff from InvestHK, and representatives who share a common background as newly established companies in Hong Kong. The Reception definitely served as a platform to connect ACT Genomics with other related organizations in order to accelerate potential collaborative opportunities in the future.  ACT Genomics would like to express appreciation of the assistance rendered by InvestHK.

Image title

June 08-09  Knowledge Transfer and Networking Opportunity at the 5th Macau Symposium on Biomedical Sciences  

ACT Genomics was invited to participate at the “Precision” symposium, organized by the Faculty of Health Sciences at the University of Macau, from June 8th to 9th.  Keynote speakers include Dr. Douglas Lowy (National Cancer Institute, USA, 2017 Lasker-DeBakey Clinical Medical Research Award), Prof. Ada Yonath (Weizmann Institute of Science, Israel, 2009 Nobel Laureate in Chemistry), and Prof. Kevin Struhl (Harvard University, USA).  This two-day symposium has provided opportunities for knowledge transfer and potential collaboration between Hong Kong, Macau and worldwide.  Furthermore, the participation reinforced the research collaboration between the Faculty of Health Sciences, University of Macau and ACT Genomics.

Image title

June 05  Seminar on Next-Generation Sequencing in Cancer Treatment at Queen Elizabeth Hospital

ACT Genomics sponsored a seminar entitled “The Coming Era of Precision Oncology – The importance of Next-Generation Sequencing (NGS) Testing in Cancer Patient Treatment” at Queen Elizabeth Hospital on June 5th, 2018. The seminar, delivered by Dr. Timothy Yip (ACT Genomics HK Lab Director), was presented to a group of practicing oncologists within the hospital.  The content highlighted the NGS technology and elaborated on the relevance and significance of precision medicine in modern cancer therapy, giving examples of how certain genetic mutations lead to recommended targeted and immune drug therapy.  ACT Genomics would like to thank Dr. Wong Kam Hung (Chief of Service, Department of Clinical Oncology, Queen Elizabeth Hospital) and Ms. Florence Wan (Secretary to Dr. Wong Kam Hung) for organizing this seminar.  With the engaged audience, ACT Genomics foresees to organize a similar seminar in the future in order to educate more oncologists in the public hospital sector on precision medicine.

Image title

May 30 Liaison with the University of Macau - Potential Research Collaborations  

ACT Genomics received a warm welcome by Prof. Deng Chuxia (Dean/Chair Professor of Faculty of Health Sciences, University of Macau) and his team on May 30th, 2018 in Macau.   It provided an opportunity to discuss each party’s research positions and to initiate potential collaborative research projects.  This occasion also created an opportunity to invite Prof. Deng Chuxia and Prof. Edwin Cheung to be speakers at the 5th Hong Kong International Oncology Symposium.

Image title


ACT Genomics Shared Cutting-Edge Technology in Taiwan Bio Forum  

ACT Genomics was invited to Taiwan Bio Forum, which was held in Harvard Medical School in USA this year. As the first speaker, ACT Genomics shared cutting-edge technology application in cancer management and precision medicine.   https://money.udn.com/money/story/11800/3200037

Image title


Image title

FDA grants Talazoparib priority review for BRCA+ breast cancer

Abstract : The FDA has accepted the NDA and granted priority review for Talazoparib (PARP inhibitor, Pfizer) for the treatment of patients with germline BRCA mutation-positive, HER2-negative locally advanced or metastatic breast cancer based on data from the EMBRACA study.     See more...

Image title

Combination of Bevacizumab and Erlotinib prolongs PFS in patients with EGFR-mutated NSCLC

Abstract : III NEJ026 trial showed clinical benefit with combination of Bevacizumab and Erlotinib in patients with with EGFR-mutated NSCLC.  See more...

Image title

Next-Generation Sequencing Found to Be Most Cost-Effective in metastatic NSCLC

Abstract : Next-generation sequencing (NGS) in metastatic NSCLC can save substantial savings compared to other strategies, according to a study presented at the 2018 ASCO Annual Meeting.   See more...

Image title

Blood test may help detect early-stage lung cancer

Abstract : Preliminary results from the Circulating Cell-Free Genome Atlas (CCGA) study suggest that cell-free DNA (cfDNA) tests could detect early-stage lung cancer with low rates of false-positive results.   See more...

Image title

The utility of multiple-gene sequencing in breast cancer is increasing

Abstract : Due to low-cost and high detection rate, multi-gene sequencing is gradually becoming the preferred choice for patients with breast cancer. However, because of the substantial racial disparity and the long turnaround time, the test result can’t be used for decision-making. To improve clinical utilization, multi-gene sequencing should overcome those two disadvantages.   See more...

Please do not reply to this email as it is sent from a non-monitored account. To contact us, please email service@actgenomics.com.

  To unsubscribe, please enter your E-Mail :